Evaluation of Balance and Physical Performance Under Dual Task Conditions in Individuals With and Without Generalized Joint Hypermobility

This study aims to evaluate balance and physical performance under dual task conditions in individuals with and without Generalized Joint Hypermobility (GJH), as determined by the Beighton score. All participants will undergo the One-Leg Stance Test and 30-Second Sit-to-Stand Test under both single-task (balance only) and dual-task (simultaneous cognitive task) conditions. The cognitive task will involve counting backward by sevens from a given number. Participants will also complete the Timed Up and Go (TUG) test under both single- and dual-task conditions. Additionally, the Berg Balance Scale (BBS) will be used for comprehensive balance assessment. Balance confidence will be evaluated using the Activities-specific Balance Confidence Scale (ABC-16), and fear of falling will be assessed with the Falls Efficacy Scale-International (FES-I). Changes in performance under dual-task conditions will be expressed as a percentage using the Dual Task Cost (DTC) formula

Study Overview

• Status: Not yet recruiting
• Conditions: Hypermobility Syndrome
• Intervention / Treatment: Other: no intervention

• Study Type: Observational
• Enrollment (Estimated): 2

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Probability Sample

Study Population

hypermobile patients and healthy controls

Description

Inclusion Criteria:

• Aged between 18 and 40 years
• A Beighton score of 4 or higher (indicative of Generalized Joint Hypermobility)
• Willingness to participate in the study

Exclusion Criteria:

• Younger than 18 or older than 40 years
• Presence of neurological disorders (e.g., stroke, multiple sclerosis, peripheral neuropathy)
• History of vestibular system disorders (e.g., benign paroxysmal positional vertigo, vestibular neuritis)
• History of orthopedic conditions affecting the lower extremities (e.g., fracture, joint replacement, ligament injury)
• Cognitive impairment preventing the execution of cognitive tasks
• Diagnosis of systemic musculoskeletal diseases (e.g., rheumatoid arthritis, Ehlers-Danlos syndrome)
• Pregnancy
• Participation in balance training or neurological/physiotherapy programs within the last 6 months

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Control group	Other: no intervention; no intervention
patients with hypermobility	Other: no intervention; no intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Performance in the One-Leg Stance Test	Assesses static balance capacity and the impact of a simultaneous cognitive task on postural control.	0 day
Performance in the 30-Second Sit-to-Stand Test	Evaluates lower extremity muscle endurance and functional strength under cognitive load	0 day
Performance in the Timed Up and Go (TUG) test	Measures dynamic balance, mobility, and the ability to maintain performance during divided attention.	0 day
Dual Task Cost (DTC) percentage	Quantifies the percentage change in performance when a cognitive task is added, reflecting dual-task interference.	0 day

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Berg Balance Scale (BBS):	Provides a comprehensive evaluation of functional balance through various static and dynamic tasks. The maximum score is 56. Higher scores indicate that good balance.	0 day
Activities-specific Balance Confidence Scale (ABC-16)	Reflects the individual's perceived confidence in performing daily activities without losing balance.The maximum score is 100, the minimum score is 0. Higher scores indicate that high confidence patient's balance.	0 day
Falls Efficacy Scale-International (FES-I):	Assesses fear of falling during daily life activities, indicating fall-related psychological concerns. Higher scores indicate that high degree fear of falling	0 day

Collaborators and Investigators

• Sponsor: Beylikduzu State Hospital

Study record dates

Study Major Dates

• Study Start (Estimated): July 1, 2025
• Primary Completion (Estimated): August 1, 2025
• Study Completion (Estimated): August 1, 2025

Study Registration Dates

• First Submitted: June 22, 2025
• First Submitted That Met QC Criteria: June 22, 2025
• First Posted (Estimated): July 1, 2025

Study Record Updates

• Last Update Posted (Estimated): July 1, 2025
• Last Update Submitted That Met QC Criteria: June 22, 2025
• Last Verified: June 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Musculoskeletal Diseases; Joint Diseases; Joint Instability
• Other Study ID Numbers: BeylikduzuStateH22

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No